CXDC [China XD Plastics Co] 10-K: (Original Filing)

[o o Large accelerated filer o Accelerated filer o Non-accelerated filer (Do not check if a smaller reporting company) x Smaller reporting company o x The aggregate market value of the voting and non-voting common equity held by non-affiliates as of June 30, 2012 was approximately $72,853,606. As of March 20, 2013, there were 47,563,772 shares of common stock, par] [Name of Director: Li Feng 董事姓名：李峰 SERVICE AGREEMENT 服 Li Feng North 3 rd Ring East Road, Chaoyang District, Beijing This Service Agreement (“Agreement”) is entered into as of 14 day of November, 2012 (“Effective Date”) between China XD Plastics Company Limited, whose principal offices are located at 500 Fifth Avenue Suite #4120, New York, NY 10004 U.S.A. and its] [CHINA XD PLASTICS COMPANY LIMITED List of Subsidiaries Name Jurisdiction of Incorporation Favor Sea Limited British Virgin Islands Xinda Holding (HK) Company Limited Hong Kong Xinda Holding (HK) US Sub Inc China XD Plastic Company Limited Harbin Representative Branch People’s Republic of China Favor Sea (US) Inc HK Engineering Plastics Company Limited Harbin Branch People’s Republic of China Heilongjiang Xinda] [Consent of Independent Registered Public Accounting Firm The Board of Directors China XD Plastics Company Limited: We consent to the incorporation by reference in the registration statements on Form S-3/A (No. 333-167423 and No. 333-164027) of China XD Plastics Company Limited of our report dated March 25, 2013, with respect to the consolidated balance sheets of China XD Plastics Company] [CERTIFICATION (1) I have reviewed this Annual Report on Form 10-K of China XD Plastics Company Limited, for the year ended December 31, 2012. (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under] [CERTIFICATION (1) I have reviewed this Annual Report on Form 10-K of China XD Plastics Company Limited, for the year ended December 31, 2012. (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under] [CERTIFICATION AS ADOPTED SARBANES - OXLEY ACT OF 2002 (1) (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Jie Han Chief Executive Officer March 25, 2013 Taylor Zhang Chief Financial Officer Financial and Accounting Officer) (Principal]

By | 2016-03-25T15:34:44+00:00 March 25th, 2013|Categories: Chinese Stocks, CXDC, SEC Original|Tags: , , , , , |0 Comments
Read More

GURE [GULF RESOURCES] 10-K: (Original Filing)

[PART I Item 1. Business 1 Item 1A. Risk Factors 11] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Gulf Resources, Inc. North Huaigao Road, Luocheng Sub-district Office, Shouguang City, Shandong China We hereby consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-177835 dated November 9, 2011) of Gulf Resources, Inc. and in the related Prospectus included therein, of our reports dated March 18, 2013, relating to] [Certification of Chief Executive Officer I, Xiaobin Liu, certify that: 1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2012 of Gulf Resources, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the] [Certification of Chief Financial Officer I, Min Li, certify that: 1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2012 of Gulf Resources, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the] [18 U.S.C. SECTION 1350 AND EXCHANGE ACT RULES 13a-14(b) AND 15d-14(b) (Section 906 of the Sarbanes-Oxley Act of 2002) (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of the operation of the Company. Dated: March 18, 2013 Xiaobin Liu Chief Executive Officer and President Dated: March 18, 2013 Min Li]

By | 2016-03-18T04:55:27+00:00 March 18th, 2013|Categories: Chinese Stocks, GURE, SEC Original|Tags: , , , , , |0 Comments
Read More

GURE [GULF RESOURCES] 10-K: PART I Item 1. Business 1 Item 1A.

[PART I Item 1. Business 1 Item 1A. Risk Factors 11] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Gulf Resources, Inc. North Huaigao Road, Luocheng Sub-district Office, Shouguang City, Shandong China We hereby consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-177835 dated November 9, 2011) of Gulf Resources, Inc. and in the related Prospectus included therein, of our reports dated March 18, 2013, relating to] [Certification of Chief Executive Officer I, Xiaobin Liu, certify that: 1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2012 of Gulf Resources, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the] [Certification of Chief Financial Officer I, Min Li, certify that: 1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2012 of Gulf Resources, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the] [18 U.S.C. SECTION 1350 AND EXCHANGE ACT RULES 13a-14(b) AND 15d-14(b) (Section 906 of the Sarbanes-Oxley Act of 2002) (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of the operation of the Company. Dated: March 18, 2013 Xiaobin Liu Chief Executive Officer and President Dated: March 18, 2013 Min Li]

By | 2016-03-18T04:56:49+00:00 March 18th, 2013|Categories: Chinese Stocks, GURE, Webplus ver|Tags: , , , , , |0 Comments
Read More

ONP [Orient Paper] 10-K: (Original Filing)

[x ¨ ¨ Large accelerated filer ¨ x Accelerated filer Non-accelerated filer ¨ (Do not check if a smaller reporting company) ¨ Smaller reporting company ¨ x Note. The aggregate market value of the voting and non-voting common stock of the issuer held by non-affiliates as of June 30, 2012 was approximately $33,674,854 (13,205,825 shares of common stock held by] [CODE OF ETHICS AND BUSINESS CONDUCT FOR OFFICERS, DIRECTORS AND EMPLOYEES OF ORIENT PAPER, INC. We are committed to honesty, just management, fairness, providing a safe and healthy environment free from the fear of retribution, and respecting the dignity due everyone. For the communities in which we live and work we are committed to observe sound environmental business practices and] [To the Board of Directors and Stockholders of Orient Paper, Inc. Internal Control – Integrated Framework We have audited the internal control over financial reporting of Orient Paper, Inc. (the “Company”) as of December 31, 2012, based on criteria established in A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of] [SARBANES-OXLEY ACT OF 2002 I, Zhenyong Liu, certify that: 1. I have reviewed this annual report on Form 10-K of Orient Paper, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [SARBANES-OXLEY ACT OF 2002 I, Winston C. Yen, certify that: 1. I have reviewed this annual report on Form 10-K of Orient Paper, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 18, 2013 Zhenyong Liu Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 18, 2013 Winston C. Yen Chief Financial Officer (principal financial and accounting officer )]

By | 2016-03-19T22:41:06+00:00 March 18th, 2013|Categories: Chinese Stocks, ONP, SEC Original|Tags: , , , , , |0 Comments
Read More

ONP [Orient Paper] 10-K: x ¨ ¨ Large accelerated filer ¨ x

[x ¨ ¨ Large accelerated filer ¨ x Accelerated filer Non-accelerated filer ¨ (Do not check if a smaller reporting company) ¨ Smaller reporting company ¨ x Note. The aggregate market value of the voting and non-voting common stock of the issuer held by non-affiliates as of June 30, 2012 was approximately $33,674,854 (13,205,825 shares of common stock held by] [CODE OF ETHICS AND BUSINESS CONDUCT FOR OFFICERS, DIRECTORS AND EMPLOYEES OF ORIENT PAPER, INC. We are committed to honesty, just management, fairness, providing a safe and healthy environment free from the fear of retribution, and respecting the dignity due everyone. For the communities in which we live and work we are committed to observe sound environmental business practices and] [To the Board of Directors and Stockholders of Orient Paper, Inc. Internal Control – Integrated Framework We have audited the internal control over financial reporting of Orient Paper, Inc. (the “Company”) as of December 31, 2012, based on criteria established in A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of] [SARBANES-OXLEY ACT OF 2002 I, Zhenyong Liu, certify that: 1. I have reviewed this annual report on Form 10-K of Orient Paper, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [SARBANES-OXLEY ACT OF 2002 I, Winston C. Yen, certify that: 1. I have reviewed this annual report on Form 10-K of Orient Paper, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 18, 2013 Zhenyong Liu Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 18, 2013 Winston C. Yen Chief Financial Officer (principal financial and accounting officer )]

By | 2016-03-19T22:42:49+00:00 March 18th, 2013|Categories: Chinese Stocks, ONP, Webplus ver|Tags: , , , , , |0 Comments
Read More

DHRM [Dehaier Medical Systems] 10-K: (Original Filing)

[] [Subsidiaries of Dehaier Medical Systems Limited Breathcare LLC [USA Company] (100% subsidiary) Beijing Dehaier Medical Technology Company Limited [PRC Company] (99% subsidiary)] [I, Ping Chen, certify that: (1) I have reviewed this Form 10-K of Dehaier Medical Systems Limited; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [Certification of Principal Financial Officer I, Charles Li, certify that: (1) I have reviewed this Form 10-K of Dehaier Medical Systems Limited; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the this period report fairly presents, in all material respects, the financial condition and results of operations of Dehaier Medical Systems Limited. Ping Chen] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the this period report fairly presents, in all material respects, the financial condition and results of operations of Dehaier Medical Systems Limited. Charles Li Chief Financial Officer (Principal Financial Officer)] [Dehaier Medical Announces 2012 Fourth Quarter and Year End Financial Results Net income up 2.91% Gross margin increased 1.28% BEIJING -- March 18, 2013 -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM) Mr. Ping Chen, Chief Executive Officer of Dehaier Medical, stated, "We are pleased with our progress in 2012 as our business strategy has proved to be the right decision]

By | 2016-03-25T07:54:42+00:00 March 18th, 2013|Categories: Chinese Stocks, DHRM, SEC Original|Tags: , , , , , |0 Comments
Read More

DHRM [Dehaier Medical Systems] 10-K:

[] [Subsidiaries of Dehaier Medical Systems Limited Breathcare LLC [USA Company] (100% subsidiary) Beijing Dehaier Medical Technology Company Limited [PRC Company] (99% subsidiary)] [I, Ping Chen, certify that: (1) I have reviewed this Form 10-K of Dehaier Medical Systems Limited; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [Certification of Principal Financial Officer I, Charles Li, certify that: (1) I have reviewed this Form 10-K of Dehaier Medical Systems Limited; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the this period report fairly presents, in all material respects, the financial condition and results of operations of Dehaier Medical Systems Limited. Ping Chen] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the this period report fairly presents, in all material respects, the financial condition and results of operations of Dehaier Medical Systems Limited. Charles Li Chief Financial Officer (Principal Financial Officer)] [Dehaier Medical Announces 2012 Fourth Quarter and Year End Financial Results Net income up 2.91% Gross margin increased 1.28% BEIJING -- March 18, 2013 -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM) Mr. Ping Chen, Chief Executive Officer of Dehaier Medical, stated, "We are pleased with our progress in 2012 as our business strategy has proved to be the right decision]

By | 2016-03-25T07:55:45+00:00 March 18th, 2013|Categories: Chinese Stocks, DHRM, Webplus ver|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMAS,] 10-K: (Original Filing)

[FORM 10-K x For the fiscal year ended December 31, 2012 or ¨ For the transition period from _________ to _____________ China Pharma Holdings, Inc. Nevada 73-1564807 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730 Title of each class Name of each] [December 24, 2012 Dear Ms. Heung Mei Tsui On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc as a director. The compensation is $16,000 per year. I look forward to working with you. Your starting date will be the December 24, 2012, and] [Re: Service about being independent director, Chairman of the Nominating and Compensation Committee, and member of the Audit Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Yingwen Zhang, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, member of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Baowen Dong, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, chairman of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Gene Michael Bennett, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an] [Loans Extension Agreement With respect to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the Company), the principal and accumulated interest totaled USD $1,354,567 and $17,122 respectively as of December 31, 2012. Because the Company temporarily did not have enough balance in its oversea account to repay the loans, Ms. Tsui and the Company unanimously agreed] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 13, 2013 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries appearing in this Annual Report on Form 10-K of China Pharma] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 14, 2013 President and Chief Executive Officer EX-32.1 10 cphi10kex321123112.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 14, 2013 (principal financial officer and principal accounting officer) EX-32.2 11 cphi10kex322123112.htm]

By | 2016-03-03T16:59:45+00:00 March 14th, 2013|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMAS,] 10-K: FORM 10-K x For the fiscal year ended

[FORM 10-K x For the fiscal year ended December 31, 2012 or ¨ For the transition period from _________ to _____________ China Pharma Holdings, Inc. Nevada 73-1564807 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730 Title of each class Name of each] [December 24, 2012 Dear Ms. Heung Mei Tsui On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc as a director. The compensation is $16,000 per year. I look forward to working with you. Your starting date will be the December 24, 2012, and] [Re: Service about being independent director, Chairman of the Nominating and Compensation Committee, and member of the Audit Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Yingwen Zhang, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, member of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Baowen Dong, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, chairman of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 24, 2012 Dear Mr. Gene Michael Bennett, On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an] [Loans Extension Agreement With respect to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the Company), the principal and accumulated interest totaled USD $1,354,567 and $17,122 respectively as of December 31, 2012. Because the Company temporarily did not have enough balance in its oversea account to repay the loans, Ms. Tsui and the Company unanimously agreed] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 13, 2013 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries appearing in this Annual Report on Form 10-K of China Pharma] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 14, 2013 President and Chief Executive Officer EX-32.1 10 cphi10kex321123112.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 14, 2013 (principal financial officer and principal accounting officer) EX-32.2 11 cphi10kex322123112.htm]

By | 2016-03-03T17:01:54+00:00 March 14th, 2013|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMAS,] 10-K: (Original Filing)

[FORM 10-K x For the fiscal year ended December 31, 2012 or For the transition period from _________ to _____________ China Pharmas, Nevada 73-1564807 (State or other jurisdiction oforporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730] [December 24, 2012 Dear Ms. Heung Mei Tsui On behalf of the Board of Directors and thempany, I am pleased to welcome you to join the Board of the China Pharmas, a director. Thempensation is $16,000 per year. I look forward to working with you. Your startingte will be the December 24, 2012, and the] [Re: Serviceout being independent director, Chairman of the Nominating andmpensationmmittee, and member of the Auditmmittee of China Pharmas, December 24, 2012 Dear Mr. Yingwen Zhang, On behalf of the Board of Directors and thempany, I am pleased to welcome you to join the Board of the China Pharmas, an independent director, Chairman of the Nominating] [Re: Serviceout being independent director, member of the Auditmmittee, and member of the Nominating andmpensationmmittee of China Pharmas, December 24, 2012 Dear Mr. Baowen Dong, On behalf of the Board of Directors and thempany, I am pleased to welcome you to join the Board of the China Pharmas, an independent director, member of the Auditmmittee,] [Re: Serviceout being independent director, chairman of the Auditmmittee, and member of the Nominating andmpensationmmittee of China Pharmas, December 24, 2012 Dear Mr. Gene Michael Bennett, On behalf of the Board of Directors and thempany, I am pleased to welcome you to join the Board of the China Pharmas, an independent director, chairman of the] [Loans Extensionreement With respect to the loans from Ms. Heung Mei Tsui to China Pharmas, (thempany), the principal and accumulated interest totaled USD $1,354,567 and $17,122 respectively of December 31, 2012. Because thempany temporarily did not have enough balance in its oversea account to repay the loans, Ms. Tsui and thempany unanimouslyreed to extend the] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Wensent to theorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our reportted March 13, 2013 relating to thensolidated financial statements of China Pharmas, and subsidiaries appearing in this Annual Report on Form 10-K of China Pharmas, for] [CERTIFICATION OF OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:March 14, 2013 President and Chief Executive Officer cphi10kex321123112.htm 10 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:March 14, 2013 (principal financial officer and principal accounting officer) cphi10kex322123112.htm 11 EX-32.2]

By | 2016-02-07T21:42:17+00:00 March 14th, 2013|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Read More
Skip to toolbar